Panda Anita, Pe'er Jacob, Aggarwal Anand, Das Hrishikesh, Kumar Abhiyan, Mohan Shalini
Cornea, Ocular Surface Disease, and Refractive Surgery Services, Dr R P Centre, All India Institute of Medical Sciences, New Delhi, India.
Am J Ophthalmol. 2008 Apr;145(4):635-638. doi: 10.1016/j.ajo.2007.12.004. Epub 2008 Feb 1.
To evaluate patients with ocular surface squamous neoplasia (OSSN) on treatment with topical mitomycin C (MMC) with regard to changes in corneal thickness and endothelial count.
Prospective, nonrandomized, interventional series.
In this prospective evaluation, 25 patients with OSSN with different clock hours of involvement (range, one to eight), age varying from 19 to 76 years, were treated with topical MMC 0.04% in a cyclic manner. Preoperative corneal thickness measurement and endothelial cell density were obtained, and the tests were repeated after one, three, and six months of complete resolution. The fellow eyes of the same patients served as controls.
Mean +/- standard deviation (SD) pachymetry and endothelial cell counts before and after instillation were 504.48 +/- 5.45 microm and 2325.76 +/- 192.52 cells/mm2 and 503.52 +/- 5.75 microm and 2297.60 +/- 192.08 cells/mm2, respectively, suggesting no significant difference in the above two parameters. Similarly, in the fellow control eyes, mean +/- SD pachymetry and endothelial cell counts before and after instillation were 502.80 +/- 4.34 microm and 2326.72 +/- 191.93 cells/mm2 and 504.64 +/- 5.19 microm and 2313.60 +/- 192.03 cells/mm2, respectively.
Topical 0.04% MMC drops do not significantly affect the corneal endothelium. However, its judicious use and long-term follow-up are mandatory.
评估接受局部丝裂霉素C（MMC）治疗的眼表鳞状上皮肿瘤（OSSN）患者的角膜厚度和内皮细胞计数变化。
前瞻性、非随机、干预性系列研究。
在这项前瞻性评估中，25例OSSN患者受累的时钟小时数不同（范围为1至8个），年龄在19至76岁之间，采用0.04%的局部MMC进行周期性治疗。术前测量角膜厚度并获得内皮细胞密度，在完全消退1、3和6个月后重复进行这些检查。同一患者的对侧眼作为对照。
滴注前后角膜厚度测量值和内皮细胞计数的平均值±标准差（SD）分别为504.48±5.45微米和2325.76±192.52个细胞/平方毫米以及503.52±5.75微米和2297.60±192.08个细胞/平方毫米，表明上述两个参数无显著差异。同样，在对侧对照眼中（滴注前后），角膜厚度测量值和内皮细胞计数的平均值±标准差分别为502.80±4.34微米和2326.72±191.93个细胞/平方毫米以及504.64±5.19微米和2313.60±192.03个细胞/平方毫米。
局部使用0.04%的MMC滴眼液不会显著影响角膜内皮。然而，必须谨慎使用并进行长期随访。
